We’ve brought together the best content from the event in one place, including session insights, blog posts, event photography and more. Explore the highlights, catch up on key conversations and revisit the ideas shaping the future of advanced therapies.
On Demand Content from Advanced Therapies Europe 2026
Key Session Write-ups
Photo Gallery
This is a snapshot of the images we've got so far from Advanced Therapies Europe 2026, we'll be adding a link to the full gallery very soon!
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
Key Discussion Points & Takeaways from #ATE26
Regulatory Harmony
Europe’s regulatory strength is also one of its biggest competitiveness challenges. Different national systems bring valuable expertise and high standards, but fragmentation can create delays, duplication and uncertainty for companies trying to run trials, develop therapies and launch products across multiple markets.
The opportunity is not necessarily to create one completely uniform system, but to make Europe far more coordinated, predictable and easier to navigate. Better regulatory alignment could help turn a collection of strong individual ecosystems into a market that can move at European scale, without compromising the standards that underpin trust and quality.
China's Growth & Europe's Competitiveness
Competition in advanced therapies is no longer defined by science alone. Across China, the US and other global markets, different approaches to speed, capital, manufacturing, industrial strategy and risk are reshaping where innovation can thrive. China’s rapid acceleration raises an important question for Europe: where can we create a genuine competitive advantage, and are we moving fast enough to use it?
Europe already has many of the foundations: world-class science, clinical expertise, talent and healthcare infrastructure. The challenge now is to build the conditions around those strengths so companies can develop, manufacture and commercialise advanced therapies here, keeping European innovation, investment and growth in Europe.
Capital and Investment
Capital in advanced therapies has not disappeared, but the bar for investment has moved. Scientific promise alone is no longer enough, with investors increasingly looking for evidence across clinical data, manufacturing, regulatory strategy, differentiation and a credible path to commercialisation. As traditional venture models become more selective, companies are also having to think differently about where funding comes from and how they structure it.
For Europe, the bigger challenge is turning world-class science into companies that can attract capital, scale and stay here. Capital follows credible execution, so strengthening the wider ecosystem around advanced therapies will be critical to keeping investment, innovation and growth in Europe.
Manufacturing in CGT
Manufacturing in advanced therapies is no longer just a technical challenge. Developers are increasingly looking for solutions that can reduce complexity, improve flexibility, lower cost of goods and support regulatory compliance, all while creating a more commercially viable path to market.
For CDMOs, technology providers, equipment companies and other solution partners, that creates a major opportunity. The organisations that can help biotech companies move from promising science to scalable, repeatable and economically viable production will play a critical role in bringing the next generation of advanced therapies to patients.
Patient Access
Scientific innovation only matters if patients can actually access the therapies being developed. In Europe, that means overcoming challenges across reimbursement, hospital infrastructure, cross-border delivery and differing national healthcare systems, all of which can affect how quickly and sustainably advanced therapies reach patients.
Access is therefore part of the innovation challenge itself. Developers, hospitals, payers, regulators and commercial partners all have a role to play in creating scalable models that work across Europe’s diverse healthcare landscape and help turn scientific progress into real patient impact.